Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Free Report) Director Steven Gannon sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $64.06, for a total value of $640,600.00. Following the transaction, the director owned 1,870 shares in the company, valued at approximately $119,792.20. This trade represents a 84.25% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Xenon Pharmaceuticals Stock Performance
XENE opened at $62.35 on Friday. The company has a market cap of $6.03 billion, a PE ratio of -13.15 and a beta of 0.62. The stock has a 50-day moving average of $61.34 and a 200-day moving average of $54.99. Xenon Pharmaceuticals Inc. has a 52-week low of $35.60 and a 52-week high of $72.66.
Xenon Pharmaceuticals (NASDAQ:XENE – Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($1.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.16) by $0.05. During the same period in the prior year, the company earned ($1.07) earnings per share. On average, research analysts predict that Xenon Pharmaceuticals Inc. will post -4.73 earnings per share for the current year.
Analyst Ratings Changes
Read Our Latest Research Report on Xenon Pharmaceuticals
Institutional Inflows and Outflows
Several institutional investors have recently added to or reduced their stakes in XENE. Jupiter Topco LLC bought a new position in Xenon Pharmaceuticals in the 2nd quarter worth approximately $252,673,000. ADAR1 Capital Management LLC bought a new stake in shares of Xenon Pharmaceuticals in the second quarter valued at approximately $10,053,000. Hsbc Holdings PLC bought a new stake in shares of Xenon Pharmaceuticals in the second quarter valued at approximately $9,143,000. Castleark Management LLC acquired a new stake in shares of Xenon Pharmaceuticals in the second quarter worth $3,728,000. Finally, Nicholas Investment Partners LP acquired a new stake in shares of Xenon Pharmaceuticals in the second quarter worth $23,893,000. 95.45% of the stock is owned by institutional investors.
Xenon Pharmaceuticals Company Profile
Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.
The company’s pipeline comprises multiple preclinical and clinical programs.
Featured Articles
- Five stocks we like better than Xenon Pharmaceuticals
- Sony and TSMC’s $4.7 Billion Venture Is About More Than Camera Sensors
- Quantum Leaps: Debt-Free as AI Storage Demand Accelerates
- NVIDIA’s $500 Billion GPU Financing Deal Fuels Path Toward $270
- Sandisk’s Margins Look Like Software. Can They Last?
Receive News & Ratings for Xenon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
